Molecular biomarkers to determine the effectiveness of targeted therapies in cancer treatment have been widely adopted in colorectal cancer (CRC), but those to predict chemotherapy sensitivity remain poorly defined. We tested our hypothesis that KRAS mutation may be a predictor of oxaliplatin sensitivity...
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 2012;18:890-900... LB Saltz,RJ Mayer,P Schaefer,... - 《Clinical Cancer Research》 被引量: 393发表: 2012年 KRAS Mutation in Stage III Colon Cancer and...
KRAS mutation in colon ca blocks Cetuximab.(Digestive Disorders)Schneider, Mary Ellen
Kopetz noted that the combination now is recommended by the National Comprehensive Cancer Network guidelines, and that Phase III trials are currently ongoing. NewsAnti cancer drugsColon cancerColorectal cancerMonoclonal antibodiesMutationNon-small cell lung cancerPhase I clinical trials (Clinical trial)...
Half of colon cancer images were captured from KRAS mutation-positive tumors and another half from KRAS mutation-negative tumors. Next, we created Image Classifier Model using Apple CreateML machine learning module. The trained and validated model was able to successfully differentiate between colon ...
A sNDA for adagrasib plus cetuximab in advanced KRAS G12C–mutated colorectal cancer was granted priority review by the FDA.
(Supplementary Fig.5A, B) in line with a synergistic model of KRAS-signaling with SNARE enablers of KRAS transport to the PM. Analysis of additional KRAS-driven tumor types (Supplementary Fig.5C–E) demonstrated a similar initial survival trend in KRAS mutant colon cancer, where KRAS was also...
The association between smoking and increased frequency of KRAS mutation in LUAD has been reported pre- viously26–30 and indicates a clear link between smoking, mutagenesis and higher incidence of cancer. Although, it is not clear whether increased mutagenesis is the sole contributor to the ...
the concept that telomere fusion is present in the early stages of cancer regardless of TP53/KRAS mutation status, mean telomere length, and telomerase activity, but also provides additional insights targeting key telomere fusion junctions which may have significant implications for colon cancer ...
•Unliketheoverexpressionoftheimmunotherapytargethumanepidermalgrowthfactorreceptor2(HER2)inbreastcancerpatients,whichismostoftenconnectedwithanamplificationoftheHER2gene,thecorrelationofEGFRproteinlevelsandgeneamplificationandtheirmeaningforEGFRimmunotherapyresponseisstillcontroversial.AsalreadyshownforEGFRproteinexpression,we...